US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PELTHOS THERAPEUTICS INC

20.58

-1.0700-4.94%

Post-market: 20.580.00000.00%16:10 EST

Volume:9.59K

Turnover:205.57K

Market Cap:66.58M

PE:-1.08

High:23.35

Open:23.35

Low:20.50

Close:21.65

52wk High:54.29

52wk Low:9.00

Shares:3.24M

Float Shares:1.37M

Volume Ratio:1.99

T/O Rate:0.70%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-19.0707

EPS(LYR):-14.2710

ROE:-83.00%

ROA:-20.64%

PB:1.14

PE(LYR):-1.44

Loading ...

Overview Company News Filings

BRIEF-Pelthos Therapeutics Inc - To Offer Securities Up To $200 Million

Pelthos Therapeutics files $200M mixed securities shelf

Pelthos Therapeutics Inc - to Offer Securities up to $200 Mln - SEC Filing

THOMSON REUTERS

Horizon Technology Finance Provides $50 Million Venture Loan Facility to Pelthos Therapeutics

Pelthos Therapeutics Secures $50 Million Loan Facility from Horizon Technology Finance

Pelthos Therapeutics Inc - Proceeds to Support Commercialization of Zelsuvmi, Launch Xepi and Xeglyze

THOMSON REUTERS

Pelthos Therapeutics Secures up to $50 Million Senior Secured Term Loan Facility From Horizon Technology Finance

THOMSON REUTERS

BRIEF-Pelthos Therapeutics Acquires Xeglyze® Topical Treatment For Head Lice

Pelthos Therapeutics Inc - Buys Xeglyze for $1.8 Mln

THOMSON REUTERS

BRIEF-Pelthos Therapeutics - On Dec 23, Enters Asset Purchase Agreement With Hatchtech - SEC Filing

Pelthos Therapeutics Acquires Xeglyze Head Lice Treatment for $1.8 Million

Pelthos Therapeutics Files Initial Beneficial Ownership Statement; Director Andrew J. Einhorn Reports No Securities Owned

BRIEF-Pelthos Therapeutics Expands Board Of Directors With The Appointment Of Andrew Einhorn

Pelthos Therapeutics Appoints Andrew Einhorn to Board of Directors

BRIEF-Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement

Pelthos Therapeutics Initiated at Buy by HC Wainwright & Co.

Pelthos Therapeutics Director Ezra M. Friedberg Sells Common Shares

Pelthos Therapeutics (PTHS) Gets a Buy from Roth MKM

Pelthos Therapeutics Inc. Announces Date for Upcoming Annual Shareholder Meeting

Pelthos Therapeutics reports $7.4 million in third quarter revenue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PTHS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTHS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTHS\",,,,,undefined,":{"symbol":"PTHS","market":"US","secType":"STK","nameCN":"PELTHOS THERAPEUTICS INC","latestPrice":20.579,"timestamp":1771016400000,"preClose":21.649,"halted":0,"volume":9592,"hourTrading":{"tag":"盘后","latestPrice":20.579,"preClose":20.579,"latestTime":"16:10 EST","volume":1,"amount":20.579,"timestamp":1771017004893,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04942491570049426,"floatShares":1368899,"shares":3235543,"eps":-19.070698,"marketStatus":"Closed President's Day","change":-1.07,"latestTime":"02-13 16:00:00 EST","open":23.35,"high":23.35,"low":20.5,"amount":205573.976,"amplitude":0.131646,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-19.070698,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":21.649,"postHourTrading":{"tag":"盘后","latestPrice":20.579,"preClose":20.579,"latestTime":"16:10 EST","volume":1,"amount":20.579,"timestamp":1771017004893,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.9945935079046402},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTHS\",,,,,undefined,":{"symbol":"PTHS","floatShares":1368899,"roa":"-20.64%","roe":"-83.00%","lyrEps":-14.271021,"volumeRatio":1.9945935079046402,"shares":3235543,"dividePrice":0,"high":23.35,"amplitude":0.131646,"preClose":21.649,"low":20.5,"week52Low":9,"pbRate":"1.14","psRate":"8.99","week52High":54.29,"institutionHeld":0,"latestPrice":20.579,"eps":-19.070698,"divideRate":0,"volume":9592,"delay":0,"ttmEps":-19.070698,"open":23.35,"prevYearClose":31,"prevWeekClose":20.579,"prevMonthClose":24.02,"prevQuarterClose":31,"fiveDayClose":22.99,"twentyDayClose":25.94,"sixtyDayClose":33.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTHS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"PTHS","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-5.3},{"market":"US","date":"2025-07-02","symbol":"PTHS","defaultRemindTime":1751463000000,"type":"split","dateTimestamp":1751428800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTHS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTHS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1764824400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PTHS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PTHS","date":"2026-02-13","current":-1.07909,"percent":0.74359,"low":-12.702408,"twenty":-10.623674,"median":-3.435432,"eighty":-1.954036,"high":-1.189404,"avg":-5.496094,"sd":3.830213,"marketCap":66823556},"quantilePoints":[{"date":"2025-07-03","current":-1.450338,"twenty":-1.398151,"median":-1.319871,"eighty":-1.241591,"marketCap":10675383},{"date":"2025-07-11","current":-2.372872,"twenty":-2.216593,"median":-1.475876,"eighty":-1.450338,"marketCap":17465810},{"date":"2025-07-18","current":-1.983069,"twenty":-1.968731,"median":-1.794665,"eighty":-1.455446,"marketCap":14596616},{"date":"2025-07-25","current":-1.97142,"twenty":-1.96909,"median":-1.819083,"eighty":-1.509032,"marketCap":14510870},{"date":"2025-08-01","current":-1.895251,"twenty":-1.972137,"median":-1.894355,"eighty":-1.668896,"marketCap":13950222},{"date":"2025-08-08","current":-1.785927,"twenty":-1.971241,"median":-1.88181,"eighty":-1.778579,"marketCap":13145529},{"date":"2025-08-15","current":-1.383693,"twenty":-1.968373,"median":-1.828044,"eighty":-1.653842,"marketCap":12505731},{"date":"2025-08-22","current":-1.565412,"twenty":-1.958336,"median":-1.793992,"eighty":-1.534031,"marketCap":14148098},{"date":"2025-08-29","current":-7.738365,"twenty":-1.968373,"median":-1.78996,"eighty":-1.553735,"marketCap":69938867},{"date":"2025-09-05","current":-10.936036,"twenty":-1.983069,"median":-1.813483,"eighty":-1.562493,"marketCap":98839226},{"date":"2025-09-12","current":-10.771103,"twenty":-7.559968,"median":-1.868816,"eighty":-1.565412,"marketCap":97348576},{"date":"2025-09-19","current":-11.212045,"twenty":-9.357396,"median":-1.887634,"eighty":-1.641655,"marketCap":101333783},{"date":"2025-09-26","current":-11.188484,"twenty":-10.771103,"median":-1.911381,"eighty":-1.642041,"marketCap":101120833},{"date":"2025-10-03","current":-8.961188,"twenty":-10.771103,"median":-1.965147,"eighty":-1.648609,"marketCap":80990668},{"date":"2025-10-10","current":-8.414925,"twenty":-10.626367,"median":-1.972316,"eighty":-1.659169,"marketCap":76053575},{"date":"2025-10-17","current":-9.593014,"twenty":-10.434506,"median":-2.154672,"eighty":-1.70259,"marketCap":86701075},{"date":"2025-10-24","current":-11.663085,"twenty":-10.626367,"median":-7.559968,"eighty":-1.70259,"marketCap":105410254},{"date":"2025-10-31","current":-11.19185,"twenty":-10.777835,"median":-7.80905,"eighty":-1.706174,"marketCap":101151254},{"date":"2025-11-07","current":-12.702408,"twenty":-10.936036,"median":-7.98408,"eighty":-1.777862,"marketCap":114803587},{"date":"2025-11-14","current":-11.772301,"twenty":-11.111066,"median":-8.995487,"eighty":-1.781447,"marketCap":106397338},{"date":"2025-11-21","current":-3.765213,"twenty":-11.111066,"median":-8.414925,"eighty":-1.785927,"marketCap":88788749},{"date":"2025-11-28","current":-3.687312,"twenty":-11.108373,"median":-7.960687,"eighty":-1.792379,"marketCap":86951740},{"date":"2025-12-05","current":-3.422448,"twenty":-11.024224,"median":-7.763609,"eighty":-1.805104,"marketCap":80705911},{"date":"2025-12-12","current":-3.133628,"twenty":-10.952193,"median":-4.332389,"eighty":-1.816843,"marketCap":73895143},{"date":"2025-12-19","current":-2.967391,"twenty":-10.936709,"median":-3.83078,"eighty":-1.833421,"marketCap":69975058},{"date":"2025-12-26","current":-3.468719,"twenty":-10.936036,"median":-3.687312,"eighty":-1.856092,"marketCap":81797046},{"date":"2026-01-02","current":-4.057747,"twenty":-10.93065,"median":-3.642809,"eighty":-1.874014,"marketCap":95687111},{"date":"2026-01-09","current":-3.672916,"twenty":-10.883527,"median":-3.665062,"eighty":-1.88181,"marketCap":86612268},{"date":"2026-01-16","current":-3.395418,"twenty":-10.806109,"median":-3.583058,"eighty":-1.88647,"marketCap":80068505},{"date":"2026-01-23","current":-3.187295,"twenty":-10.776489,"median":-3.555764,"eighty":-1.893817,"marketCap":75160682},{"date":"2026-01-30","current":-3.374475,"twenty":-10.771103,"median":-3.506679,"eighty":-1.898477,"marketCap":79574636},{"date":"2026-02-06","current":-3.052604,"twenty":-10.742156,"median":-3.468719,"eighty":-1.919625,"marketCap":71984487},{"date":"2026-02-13","current":-2.833747,"twenty":-10.623674,"median":-3.435432,"eighty":-1.954036,"marketCap":66823556}],"updateTime":1771249649899},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTHS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608813857","title":"BRIEF-Pelthos Therapeutics Inc - To Offer Securities Up To $200 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608813857","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608813857?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:55","pubTimestamp":1770069344,"startTime":"0","endTime":"0","summary":"BRIEF-Pelthos Therapeutics Inc - To Offer Securities Up To $200 MillionFeb 2 (Reuters) - Pelthos Therapeutics Inc PTHS.A:PELTHOS THERAPEUTICS INC - TO OFFER SECURITIES UP TO $200 MILLION - SEC FILINGFurther company coverage: PTHS.A ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2608136328","title":"Pelthos Therapeutics files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2608136328","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608136328?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:50","pubTimestamp":1770069024,"startTime":"0","endTime":"0","summary":"16:47 EST Pelthos Therapeutics (PTHS) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-files-200m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-files-200m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTHS","BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2608818718","title":"Pelthos Therapeutics Inc - to Offer Securities up to $200 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608818718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608818718?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:46","pubTimestamp":1770068817,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2603293597","title":"Horizon Technology Finance Provides $50 Million Venture Loan Facility to Pelthos Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2603293597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603293597?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:10","pubTimestamp":1768511416,"startTime":"0","endTime":"0","summary":"Horizon Technology Finance Corporation has announced the provision of a $50 million venture loan facility to Pelthos Therapeutics Inc., with an initial funding of $30 million and an additional $20 million available to support future growth. The facility is designed to help Pelthos promote its dermatology products ZELSUVMI and Xepi Cream, as well as support the launch of Xeglyze. The loan proceeds will be used for working capital and general growth initiatives. Horizon, known for its experience in lending to life science companies, structured the financing to align with Pelthos’ growth strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Horizon Technology Finance Corporation published the original content used to generate this news","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL2zdjjz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRZN","BK4135","BK4139","PTHS"],"gpt_icon":0},{"id":"2603682645","title":"Pelthos Therapeutics Secures $50 Million Loan Facility from Horizon Technology Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682645","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682645?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:32","pubTimestamp":1768311139,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance Corporation. The initial funding of $30 million was provided at closing, with an additional $20 million available upon achieving certain milestones. The loan carries an interest rate of Prime plus 3.75% , with a term of sixty months and interest-only payments until amortization begins at month thirty-six, or month forty-eight if specific milestones are met. In connection with the financing, Pelthos issued Horizon warrants to purchase 65,488 shares of its common stock at an exercise price of $27.49 per share. The proceeds will support the commercialization of ZELSUVMI, the launch of Xepi and Xeglyze, and general corporate purposes. The funding is described as minimally dilutive, with most capital raised being non-dilutive to existing shareholders except for the warrants issued. Oppenheimer & Co. served as financial advisor, with Morgan, Lewis & Bockius LLP and S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL2s2gqH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4139","BK4127","HRZN","OPY","PTHS"],"gpt_icon":0},{"id":"2603826636","title":"Pelthos Therapeutics Inc - Proceeds to Support Commercialization of Zelsuvmi, Launch Xepi and Xeglyze","url":"https://stock-news.laohu8.com/highlight/detail?id=2603826636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603826636?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:30","pubTimestamp":1768311001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA2TYJPT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HRZN","PTHS","BK4135"],"gpt_icon":0},{"id":"2603682363","title":"Pelthos Therapeutics Secures up to $50 Million Senior Secured Term Loan Facility From Horizon Technology Finance","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682363?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:30","pubTimestamp":1768311001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA2TYJPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTHS","HRZN","BK4135","BK4139"],"gpt_icon":0},{"id":"2601388767","title":"BRIEF-Pelthos Therapeutics Acquires Xeglyze® Topical Treatment For Head Lice","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388767","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601388767?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:28","pubTimestamp":1767623331,"startTime":"0","endTime":"0","summary":"BRIEF-Pelthos Therapeutics Acquires Xeglyze Topical Treatment For Head LiceJan 5 (Reuters) - Pelthos Therapeutics Inc PTHS.A:PELTHOS THERAPEUTICS ACQUIRES XEGLYZE (ABAMETAPIR) TOPICAL TREATMENT FOR HE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7XF9ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2601886013","title":"Pelthos Therapeutics Inc - Buys Xeglyze for $1.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886013?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:30","pubTimestamp":1767616200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA7XF9ND:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2600093765","title":"BRIEF-Pelthos Therapeutics - On Dec 23, Enters Asset Purchase Agreement With Hatchtech - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600093765","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600093765?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:00","pubTimestamp":1767391231,"startTime":"0","endTime":"0","summary":"BRIEF-Pelthos Therapeutics - On Dec 23, Enters Asset Purchase Agreement With Hatchtech - SEC FilingJan 2  - Pelthos Therapeutics Inc PTHS.A:PELTHOS THERAPEUTICS INC - ON DEC 23, ENTERS ASSET PURCHASE AGREEMENT WITH HATCHTECH - SEC FILINGPELTHOS THERAPEUTICS INC - HATCHTECH SELLS RIGHTS TO XEGLYZE PRODUCT TO CO FOR $1.8 MILLION  - SEC FILINGSource text: [ID:n0001753926-26-000010]Further company coverage: PTHS.A ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y301O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2600093457","title":"Pelthos Therapeutics Acquires Xeglyze Head Lice Treatment for $1.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2600093457","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600093457?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:46","pubTimestamp":1767390401,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has acquired Xeglyze , an FDA-approved prescription medication for the topical treatment of head lice in patients 6 months of age and older, from Hatchtech Pty Ltd. for $1.8 million. Xeglyze, approved by the U.S. Food and Drug Administration in July 2020, is a single-application treatment that does not require nit combing and is designed to address head lice infestations, which are especially common among children. Pelthos plans to relaunch Xeglyze in the first half of 2027 and will commercialize the product worldwide. No future milestone, royalty, or other payments are owed to Hatchtech as part of the deal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL7F7Pt5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2595575878","title":"Pelthos Therapeutics Files Initial Beneficial Ownership Statement; Director Andrew J. Einhorn Reports No Securities Owned","url":"https://stock-news.laohu8.com/highlight/detail?id=2595575878","media":"Reuters","labels":["executive","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595575878?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:16","pubTimestamp":1767042998,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Andrew J. Einhorn as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL5w8Dyd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Pelthos Therapeutics Files Initial Beneficial Ownership Statement; Director Andrew J. Einhorn Reports No Securities Owned","news_tag":"executive,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2593449893","title":"BRIEF-Pelthos Therapeutics Expands Board Of Directors With The Appointment Of Andrew Einhorn","url":"https://stock-news.laohu8.com/highlight/detail?id=2593449893","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593449893?lang=en_us&edition=fundamental","pubTime":"2025-12-24 07:12","pubTimestamp":1766531521,"startTime":"0","endTime":"0","summary":"BRIEF-Pelthos Therapeutics Expands Board Of Directors With The Appointment Of Andrew EinhornDec 23 (Reuters) - Pelthos Therapeutics Inc PTHS.A:PELTHOS THERAPEUTICS EXPANDS BOARD OF DIRECTORS WITH THE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUA5MVWFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2593544637","title":"Pelthos Therapeutics Appoints Andrew Einhorn to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2593544637","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593544637?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:31","pubTimestamp":1766529068,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has appointed Andrew J. Einhorn to its Board of Directors, expanding the board to eight members. Einhorn will also join the Audit Committee and the Compensation Committee. He brings over four decades of experience in finance, capital markets, and life sciences, having previously held CFO positions at several biotechnology companies and currently serving as a consultant at Danforth Advisors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL9HW9w4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2588188066","title":"BRIEF-Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188066","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588188066?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:19","pubTimestamp":1764857974,"startTime":"0","endTime":"0","summary":"BRIEF-Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Dec 4 (Reuters) - Pelthos Therapeutics Inc PTHS.A:PELTHOS THERAPEUTICS SIGNS MAJOR PHARMACY BENEFIT MANAGER AGREEMENT EXPANDIN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA9QNZWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2588560045","title":"Pelthos Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588560045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588560045?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:14","pubTimestamp":1764764040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTHS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 07:14 ET (12:14 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4139","PTHS","BK4007"],"gpt_icon":0},{"id":"2586261442","title":"Pelthos Therapeutics Director Ezra M. Friedberg Sells Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586261442","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586261442?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:37","pubTimestamp":1764178661,"startTime":"0","endTime":"0","summary":"Ezra M. Friedberg, a Director of Pelthos Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL3y2sTb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pelthos Therapeutics Director Ezra M. Friedberg Sells Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2586449447","title":"Pelthos Therapeutics (PTHS) Gets a Buy from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2586449447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586449447?lang=en_us&edition=fundamental","pubTime":"2025-11-25 13:35","pubTimestamp":1764048915,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics received a Buy rating and a $57.00 price target from Roth MKM analyst Jonathan Aschoff today. According to TipRanks, Aschoff i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pelthos-therapeutics-pths-gets-a-buy-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pelthos-therapeutics-pths-gets-a-buy-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2583682180","title":"Pelthos Therapeutics Inc. Announces Date for Upcoming Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682180","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682180?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:50","pubTimestamp":1763157043,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has announced that it will hold its 2025 Annual Meeting of Shareholders online on December 17, 2025. Shareholders will have the opportunity to consider and vote on several items during the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL8Gy4Nj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2583356458","title":"Pelthos Therapeutics reports $7.4 million in third quarter revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2583356458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583356458?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:50","pubTimestamp":1763034644,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. reported total revenue of $7.4 million for the third quarter ended September 30, 2025, compared to no revenue in the same period of 2024. Net product revenues from the commercial launch of ZELSUVMI, its FDA-approved at-home treatment for molluscum contagiosum, were $7.1 million, while license and collaboration revenues were $0.3 million. The company reported a net loss of $16.2 million, or $5.30 per basic and fully diluted common share. Cash and cash equivalents increased to $14.2 million as of September 30, 2025, from $0.5 million at the end of 2024, following a $50.1 million equity private placement. During the quarter, 2,716 units of ZELSUVMI were dispensed by 1,169 unique prescribers. The merger of Channel Therapeutics Corporation and LNHC, Inc. was completed to form Pelthos Therapeutics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL1kt5HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}